Latest News
The Tytgat Foundation continues to advance its mission through a series of recent initiatives and collaborations. From awarding promising researchers whose work shows exceptional potential, to organizing ceremonies that celebrate breakthroughs in cancer research, the Foundation actively highlights scientific excellence. Strategic partnerships with leading academic institutions and philanthropic organizations further strengthen its capacity to support innovative projects. Through these ongoing efforts, the Foundation not only honors past achievements but also fosters a dynamic environment where cutting-edge research can thrive and translate into tangible benefits for patients and society.
Archive
The 2020 Tytgat Foundation Prize was attributed to Prof. Dr Constantinescu for his remarkable work
On November 27, Stefan Constantinescu, professor at the Faculty of Medicine and Dentistry of UCLouvain and researcher at the de Duve Institute and at the Ludwig Institute for Cancer Research Brussels, received the 15th Alexandre and Gaston Tytgat Foundation Prize.
The Tytgat Foundation Supports KickCancer
The Alexandre and Gaston Tytgat Foundation, together with the entire family, holds a deep appreciation for the remarkable work carried out by Delphine Heenen, founder of KickCancer.
The 2017 Tytgat Foundation Prize was attributed to Olivier Feron for Pioneering Research on Tumor Metabolism
Professor Olivier Feron has been recognized for his pioneering research on how tumors interact with their microenvironment. His work reveals how cancer cells adapt their metabolism to survive in hostile conditions, and how these metabolic changes in turn reshape the tumor niche — offering new insights for future therapies.
Tytgat Foundation Awards Prof. Chris Marine the 2014 Prize for Groundbreaking Cancer Researchking Cancer Research in 2014
Prof. Chris Marine has been recognized with the 2014 Tytgat Foundation Award for his pioneering work on p53 biology and cancer therapy. His research explores how tumor suppressor loss, particularly of p53, creates vulnerabilities in cancer cells that can be exploited via synthetic lethal interactions and targeted microRNA therapies — opening promising avenues for selective, tumor-specific treatments.